Generate:Biomedicines has entered a strategic collaboration with the Roswell Park Comprehensive Cancer Center in Erie County, New York, US, to accelerate the development of new oncology cell therapies leveraging generative artificial intelligence.
The partnership will focus on the discovery and development of chimeric antigen receptor (CAR) T-cell therapies and armouring technologies for up to three targets, including ovarian cancer and other solid tumours.
The companies will collaborate to develop optimised cell therapies involving the engineering of a patient’s T cells to recognise and destroy tumours.
The collaboration leverages the Generate platform’s programmability and scalability along with Roswell Park’s cell therapy design, clinical development and manufacturing expertise.
Generate:Biomedicines and Roswell Park will divide costs related to research and development, and profits derived from the commercialisation of products resulting from their collaboration.
Roswell Park will function as a location for Phase I and II clinical trials, as well as recommend lead investigators.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
New York Governor Kathy Hochul recently revealed that Roswell Park Comprehensive Cancer Center in Buffalo will host a $98m cell and gene therapy hub.
The ongoing collaboration builds on the momentum generated by the new hub, partly funded by New York State, which will transform Roswell Park’s current good manufacturing practice facilities into the largest academic cell therapy centre in the US.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.